All releases

Jun 09, 2017

Verseon Corporation (“Verseon” or the “Company”)

Verseon to present preclinical data on diabetic macular edema program and update on anticoagulation program at BIO 2017

FREMONT, Calif.—Verseon, a technology-based pharmaceutical company employing a computer-driven platform to develop a diverse drug pipeline, today announces that it will present its most advanced drug programs at the 2017 BIO International Conference, one of the world’s largest biotechnology events, held June 19–22, 2017 in San Diego.

Dr. David Kita, Vice President of R&D at Verseon, will present preclinical results on the Company’s plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME), a major cause of blindness worldwide that affects people with diabetes. The presentation will include pharmacokinetic data indicating that Verseon’s drug candidates can be administered as eye drops. Moreover, some of Verseon’s kallikrein inhibitors are suitable for oral dosing.

A second presentation will provide an update on Verseon’s anticoagulation program. The Company’s direct thrombin inhibitors have demonstrated efficacy comparable to existing anticoagulants in preclinical testing, but lower bleeding risk. In addition to results on Verseon’s first development candidate, which shows significantly lower renal clearance than the current anticoagulants, Dr. Kita will also present new preclinical data on another promising lead candidate with a distinct chemotype.

“Our computer-driven approach to drug discovery has allowed us to develop multiple promising candidates across our pipeline,” said Dr. Kita. “We are especially excited to share preclinical results on our DME candidates, which can potentially have a positive impact on millions of patients worldwide.”

Details of the presentations are as follows:

Anticoagulation program
Date and Time: Monday, June 19, 2017; 4:45 p.m.
Location: Company Presentation Theater 2
Abstract: https:/

Diabetic macular edema program
Date and Time: Thursday, June 22, 2017; 11:45 a.m.
Location: Company Presentation Theater 2

About Verseon’s diabetic macular edema program

Verseon has developed a new class of potent, selective compounds for the treatment of diabetic macular edema. The Company’s plasma kallikrein inhibitors target a validated pathway addressing an underlying cause of the disease. In preclinical testing, Verseon’s inhibitors show favorable biochemical properties permitting either oral or topical (eye drop) administration.

About Verseon’s anticoagulation program

Verseon’s potent, highly selective, oral direct thrombin inhibitors act through reversible covalent inhibition, a unique mode of action. Preclinical studies show that Verseon’s inhibitors act as effective anticoagulants in multiple efficacy studies, but do not disrupt platelet function. This unique feature could explain their observed low bleeding risk. One of Verseon’s lead candidates furthermore shows very low renal clearance, a highly desirable property for patients with impaired renal function.

About Verseon

Verseon Corporation (, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.

About BIO International Convention 2017

The BIO International Convention is one of the world’s largest gatherings of the biotechnology industry, with industry-leading investor and partnering meetings held around the world. With 16,000+ attendees, 1,800+ exhibitors, and 500+ companies, it represents an ideal platform for biopharma’s top people and most innovative technologies. BIO 2017, organized by the Biotechnology Innovation Organization (BIO), will be held San Diego, June 19–22, 2017.

- Ends -

For further information please contact

Verseon Corporation
Tina Schlafly +1 (510) 225 9000
Cenkos Securities (NOMAD and Joint Broker)
Neil McDonald / Beth McKiernan +44 (0) 20 7397 8900
Cantor Fitzgerald Europe (Joint Broker)
Marc Milmo / Phil Davies / Callum Butterfield +44 (0) 20 7894 7000
Mirabaud Securities LLP (Joint Broker)
Peter Krens +44 (0) 20 7321 2508

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers)
Henry Harrison-Topham / Jamie Hooper +44 (0) 20 7466 5000

For trade and pharma media enquiries, please contact

Vane Percy & Roberts
Simon Vane Percy +44 (0) 1737 821 890


This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook,” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions, and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors.